GH Research PLC
GHRS
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.9B
$28.23
▲ +1.11%
P/E
-28.23
Mkt Cap
$1.9B
52-Wk Range
$11.83–$31.44
52-Week Range
$11.83 - $31.44
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 109.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary 5-MeO-DMT formulations with novel delivery mechanisms
- Advanced clinical development stage with completed Phase 1/2 trials
- First-mover advantage in psychedelic-assisted medicine for TRD
- Diversified product pipeline addressing multiple neuropsychiatric indications
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Advancement of GH001 through Phase 2/3 clinical trials toward FDA approval
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+40.3% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying GHRS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.23 vs -$0.29 consensus (+19.6% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+19.6%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 10, 2026
vs Industry
How GHRS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related